ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CD163

CD163

概要

Name:Scavenger receptor cysteine-rich type 1 protein M130
Target Synonym:CD163,M130,Scavenger receptor cysteine-rich type 1 protein M130,sCD163,CD163 Molecule,Hemoglobin Scavenger Receptor,CD163 Antigen,Macrophage-Associated Antigen,SCARI1,MM130
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
CD3-H52E8 Human Human CD163 Protein, His Tag
CD3-H52E8-structure
CD3-H52E8-sds
ACRO Quality

Synonym Name

CD163,M130

Background

Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tetrachlorodecaoxide TCDO; WF-10; OXO-K993 Approved Nuvox Pharma LLC WF10, Oxoferin, Immunokine Thailand Rhinitis, Allergic; Inflammation null 1997-01-01 Diabetic Foot; HIV Infections; Rhinitis, Allergic; Inflammation Details
Tetrachlorodecaoxide TCDO; WF-10; OXO-K993 Approved Nuvox Pharma LLC WF10, Oxoferin, Immunokine Thailand Rhinitis, Allergic; Inflammation null 1997-01-01 Diabetic Foot; HIV Infections; Rhinitis, Allergic; Inflammation Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
OR-2805 OR-2805 Phase 2 Clinical OncoResponse Inc Solid tumours; Leiomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Liposarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details
OR-2805 OR-2805 Phase 2 Clinical OncoResponse Inc Solid tumours; Leiomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Liposarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details

This web search service is supported by Google Inc.

totopphone